In the quest for coordination compounds with potential applications in energy conversion processes, a new series of four Ir(III) complexes (C1–4) of the type [Ir(R-ppy)₂(Ln)](PF₆), where R-ppy = 2-phenylpyridine (ppy) or 2,4-difluorophenylpyridine (F₂-ppy) and Ln = 1-methyl-1H-pyrazole[3′,4′:5,6]pyrazino[2,3-f][1,10]phenanthroline (L1) or thieno[3′,4′:5,6]pyrazino[2,3-f][1,10]phenanthroline (L2) has been synthesized. The photophysical properties of these compounds have been thoroughly characterized by both steady-state and time-resolved spectroscopic techniques, pointing out a complex interplay between excited states of different nature that plays a crucial role in the deactivation processes. In the case of complexes C1–2 that feature the same L1 ancillary ligand, the lowest excited states at room temperature are characterized by an admixture between the ³MLCT/³LLCT and ³LC states, with an almost pure ³LC character in C2. For C3–4, the admixture among charge-transfer and ligand-centred states is negligible, due to the appreciably low energy of the LC one, which, however, plays a non-innocent role in the deactivation pathway of the triplet charge-transfer emissive states of complexes C3–4. This work thus highlights the importance of a detailed comprehension of the photophysical properties of Ir(III) complexes in view of their use in energy transformation systems.

Background: The extended-spectrum beta-lactamase (ESBL) Klebsiella pneumoniae is one of the leading causes of health-associated infections (HAIs), whose antibiotic treatments have been severely reduced. Moreover, HAI bacteria may harbor pathogenic factors such as siderophores, enzymes, or capsules, which increase the virulence of these strains. Thus, new therapies, such as antimicrobial photodynamic inactivation (aPDI), are needed. Method: A collection of 118 clinical isolates of K. pneumoniae was characterized by susceptibility and virulence through the determination of the minimum inhibitory concentration (MIC) of amikacin (Amk), cefotaxime (Cfx), ceftazidime (Cfz), imipenem (Imp), meropenem (Mer), and piperacillin–tazobactam (Pip–Taz); and, by PCR, the frequency of the virulence genes K2, magA, rmpA, entB, ybtS, and allS. Susceptibility to innate immunity, such as human serum, macrophages, and polymorphonuclear cells, was tested. All the strains were tested for sensitivity to the photosensitizer PSIR-3 (4 µg/mL) in a 17 µW/cm² for 30 min aPDI. Results: A significantly higher frequency of virulence genes in ESBL than non-ESBL bacteria was observed. The isolates of the genotype K2+, ybtS+, and allS+ display enhanced virulence, since they showed higher resistance to human serum, as well as to phagocytosis. All strains are susceptible to the aPDI with PSIR-3 decreasing viability in 3log10. The combined treatment with Cfx improved the aPDI to 6log10 for the ESBL strains. The combined treatment is synergistic, as it showed a fractional inhibitory concentration (FIC) index value of 0.15. Conclusions: The aPDI effectively inhibits clinical isolates of K. pneumoniae, including the riskier strains of ESBL-producing bacteria and the K2+, ybtS+, and allS+ genotype. The aPDI with PSIR-3 is synergistic with Cfx.

Multidrug-resistant bacteria, such as ESBL producing-Klebsiella pneumoniae, have increased substantially, encouraging the development of complementary therapies such as photodynamic inactivation (PDI). PDI uses photosensitizer (PS) compounds that kill bacteria using light to produce reactive oxygen species. We test Ru-based PS to inhibit K. pneumoniae and advance in the characterization of the mode of action. The PDI activity of PSRu-L2, and PSRu-L3, was determined by serial micro dilutions exposing K. pneumoniae to 0.612 J/cm ² of light dose. PS interaction with cefotaxime was determined on a collection of 118 clinical isolates of K. pneumoniae. To characterize the mode of action of PDI, the bacterial response to oxidative stress was measured by RT-qPCR. Also, the cytotoxicity on mammalian cells was assessed by trypan blue exclusion. Over clinical isolates, the compounds are bactericidal, at doses of 8 µg/mL PSRu-L2 and 4 µg/mL PSRu-L3, inhibit bacterial growth by 3 log₁₀ (>99.9%) with a lethality of 30 min. A remarkable synergistic effect of the PSRu-L2 and PSRu-L3 compounds with cefotaxime increased the bactericidal effect in a subpopulation of 66 ESBL-clinical isolates to > 6 log₁₀ with an FIC-value of 0.16 and 0.17, respectively. The bacterial transcription response suggests that the mode of action occurs through Type II oxidative stress. The upregulation of the extracytoplasmic virulence factors mrkD, magA, and rmpA accompanied this response. Also, the compounds show little or no toxicity in vitro on HEp-2 and HEK293T cells. Through the type II effect, PSs compounds are bactericidal, synergistic on K. pneumoniae, and have low cytotoxicity in mammals.

Four new mixed ligand Cu(I) complexes bearing methoxycarbonyl imidoyl-indazole and bis[2-(diphenylphosphino)-phenyl]ether (POP) ligands were synthesized and characterized by variable-temperature NMR, FT-IR, EA and HRMS. For three of them, the molecular structures were obtained by X-ray diffraction analysis. The electrochemical and absorption–emission properties of all the complexes were investigated by using cyclic voltammetry, UV-Vis spectroscopy, and spectrofluorometric measurements in a CH₂Cl₂ solution at room temperature and in different solid-state matrices. In addition, quantum chemical computations were performed to gain insight into their electronic and photophysical properties. The complexes showed an MLCT band, which is more influenced by the position of the electron-withdrawing methoxycarbonyl substituent in the indazole ring rather than by the π-extension introduced by the alkene moiety. Besides, all the complexes were found to be weak emitters in the CH₂Cl₂ solution while they were brighter emitters in the solid-state.